Search for a trial

A Randomised, Double-blind, Active Treatment Study to Induce
Clinical Response and/or Remission with GSK1605786A in
Subjects with Moderately-to-Severely Active Crohn*s Disease

Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…

An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn*s Disease (CCX114644)

Primary: Safety and tolerability. Secondary: Effectiveness, quality of life, healthcare resource utilisation, work productivity.